OncoMatch/Clinical Trials/NCT04430452
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Is NCT04430452 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Tremelimumab for advanced hepatocellular carcinoma.
Treatment: Durvalumab · Tremelimumab — This phase II trial studies how well standard of care hypofractionated radiation therapy followed by durvalumab with or without tremelimumab works in treating patients with hepatocellular cancer (liver cancer) that has spread to other places in the body (advanced) and that is growing, spreading, or getting worse (progressing). In some patients, cancer cells and immune cells start to express signals that stop the body's immune system from killing the cancer. New drugs being developed, such as durvalumab and tremelimumab, are designed to target and block these signals and may help increase the immune response to prevent or slow down cancer growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may help the immune system work even better. Giving durvalumab with or without tremelimumab after radiation therapy may work better than radiation therapy alone in treating patients with liver cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IIIA, IIIB, IV, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-L1 inhibitor (durvalumab)
prior durvalumab excluded
Cannot have received: CTLA-4 inhibitor
Prior treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or PD-L1 inhibitor.
Lab requirements
Blood counts
Hemoglobin >= 9.0 g/dL; Absolute neutrophil count >= 1,200/mcL; Platelet count >= 60,000/mcL
Kidney function
Creatinine clearance > 30 mL/min by Cockcroft Gault formula
Liver function
Child Pugh score of A, B7, or B8 provided other liver function criteria are met; Serum bilirubin <= 1.5 x institutional ULN (except Gilbert's syndrome); AST <= 2.5 x ULN unless liver metastases present (then <= 5 x ULN); INR < 1.5
Child Pugh score of A, B7, or B8 provided other liver function criteria are met. Hemoglobin >= 9.0 g/dL Absolute neutrophil count >= 1,200/mcL Platelet count >= 60,000/mcL Serum bilirubin <= 1.5 x institutional upper limit of normal. This will not apply to patients with confirmed Gilbert's syndrome ... AST <= 2.5 x institutional upper limit of normal unless liver metastases are present in which case it can be <= 5 x upper limit of normal (ULN) INR < 1.5 Creatinine clearance > 30 mL/min by Cockcroft Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify